MBL Deficiency: Causes, Symptoms, and Treatment

Mannose-binding lectin (MBL) deficiency is one of the most common immune deficiencies in humans, affecting more than one in ten people depending on how the cutoff is drawn, yet the vast majority of those affected never know it.¹ MBL is a protein that circulates in the blood and acts as an early-warning scout for the immune system, latching onto sugar patterns on the surfaces of bacteria and fungi and triggering a cascade that helps destroy them. When the gene responsible for MBL is disrupted by common mutations, your body produces little or none of the protein. For some people this gap is invisible; for others, especially young children and those with additional immune problems, it can mean recurrent infections and a range of subtler health consequences.

What MBL Does in a Healthy Immune System

MBL belongs to the innate immune system, the branch of your defenses that works immediately and without needing to “learn” about a specific germ first. It is classified as a pattern recognition molecule, meaning it detects and binds to repeating sugar structures, particularly mannose, on the surfaces of microbes.² Once MBL locks onto a pathogen, it activates a chain reaction called the lectin pathway of complement. This pathway involves enzymes called MBL-associated serine proteases (MASPs). One of these enzymes, MASP-1, switches on first, then activates MASP-2, and together they kick off the downstream destruction of the invader.³

The practical result of this cascade is twofold. First, the complement system tags the pathogen’s surface with proteins that act as “eat me” signals for white blood cells. Second, complement activation can directly punch holes in the membranes of certain microbes, killing them outright. When MBL is absent or present only at very low levels, this entire lectin arm of complement fails to fire, leaving the other two complement pathways (classical and alternative) to pick up the slack. Often they can, which is why most MBL-deficient people stay healthy. But there are situations where the lectin pathway matters a great deal, and that is where trouble starts.

Genetic Causes of MBL Deficiency

MBL is produced mainly by the liver and encoded by the MBL2 gene. Humans actually carry a second gene, MBL1, but it was silenced long ago in evolutionary history and no longer makes a functional protein.⁴ That means everything rides on MBL2. Three well-known point mutations in the first coding region of MBL2 disrupt the protein’s ability to fold into the large, functional shapes it needs to work properly. These mutations are conventionally labeled B, C, and D, and they are strikingly common across different populations worldwide.

The C variant is found mainly in sub-Saharan African populations, while the B variant predominates elsewhere, a pattern that likely reflects early human migration out of Africa.⁵ In addition to mutations in the coding region, variations in the promoter region of MBL2 (the part of the gene that controls how much protein is made) further modulate blood levels. Some people inherit a combination of a structural mutation on one chromosome and a low-producing promoter on the other, driving their MBL levels down to essentially zero. Others carry a single structural mutation and have intermediate levels that may or may not be clinically relevant.

Because MBL deficiency arises from inherited gene variants rather than acquired damage, it is present from birth. It is not a disease you “catch” or that develops over time, though its clinical significance can shift depending on your age, other immune capacities, and what infections you encounter.

How Common Is MBL Deficiency

MBL deficiency is remarkably prevalent. Depending on the threshold used to define “deficient,” more than 10% of people in the general population qualify.¹ Some estimates run even higher. The frequency varies by ethnic background: certain sub-Saharan African and South American indigenous populations carry structural variants at especially high rates, while among indigenous Australians the deficiency alleles are virtually absent.⁵

The fact that so many people worldwide carry MBL2 variants that reduce or eliminate the protein has puzzled researchers. If MBL were truly essential for survival, you would expect natural selection to have wiped out deficiency alleles long ago. A large genetic study of 24 worldwide populations found that the pattern of MBL2 variation fits neutral evolution, meaning these alleles spread through random genetic drift and human migration rather than being actively favored or penalized by natural selection.⁶ That said, the question is not entirely settled. Some researchers have argued that low MBL could actually protect against intracellular pathogens such as tuberculosis and leprosy, or against inflammatory damage in cardiovascular disease, providing a possible selective advantage that keeps these variants circulating.⁴

When MBL Deficiency Causes Problems

A large population-based study of MBL-deficient adults found that most were asymptomatic, suggesting that MBL deficiency alone is generally not enough to cause obvious disease in otherwise healthy people.⁷ The problems tend to surface in specific contexts: when the rest of the immune system is also weakened, when a person is very young, or when another immune deficit coexists.

The clearest vulnerability window is in infancy and early childhood. Between roughly five and eighteen months of age, a baby’s maternal antibodies have been used up but the child’s own adaptive immune system has not yet matured enough to produce specific antibodies efficiently. During this gap, MBL serves as a crucial backup. Children with low MBL who pass through this window are more prone to recurrent respiratory infections.⁸ In many cases, once the adaptive immune system catches up, the frequency of infections drops back to normal.

In adults, MBL deficiency becomes clinically important mainly when it overlaps with other immune deficits. Patients who are also deficient in IgA, for example, experience more severe infections when MBL is simultaneously low than they do with either deficit alone.⁹ Similarly, people undergoing chemotherapy or organ transplant recipients on immunosuppressive drugs may find that missing MBL tips the balance from manageable infection risk to serious trouble. MBL deficiency on its own rarely lands an otherwise healthy adult in the hospital, but layered on top of other vulnerabilities it can be the straw that breaks the camel’s back.

Infections That Hit MBL-Deficient People Hardest

MBL does not defend equally against all pathogens. Its sugar-binding ability is especially useful against yeasts and fungi. In laboratory studies, sera from MBL-deficient individuals showed reduced ability to deposit complement on yeast surfaces and decreased uptake of Candida albicans by neutrophils, the white blood cells that engulf and kill microbes. Adding purified MBL back to the serum restored both complement deposition and phagocytosis.¹⁰ A separate study confirmed that Candida species were particularly strong activators of the lectin pathway compared to common bacteria, reinforcing the idea that MBL is especially critical for antifungal defense.¹¹

This matters clinically because invasive fungal infections, while relatively uncommon in healthy people, can be devastating in hospital settings, in premature infants, and in immunocompromised patients. An MBL-deficient person in any of those situations is at higher risk than someone with normal MBL levels. For everyday bacterial infections, the picture is less dramatic. MBL binds to many bacteria, but the alternative and classical complement pathways usually compensate well enough that the absence of lectin-pathway activation is not catastrophic.

Connections to Autoimmune Disease

The relationship between MBL and autoimmunity is counterintuitive. You might expect that a weakened immune component would simply mean more infections, but MBL deficiency has also been linked to autoimmune conditions, particularly systemic lupus erythematosus (SLE). In a study of Brazilian patients, those with SLE had a higher frequency of mild and moderate MBL deficiency compared to healthy controls, and among the MBL-deficient SLE patients, lupus nephritis (kidney inflammation caused by lupus) was more common.¹²

One explanation is that MBL helps clear dead and dying cells from the body. When cells undergo programmed death, their surfaces become coated with the same sugar molecules that MBL recognizes on microbes. Without adequate MBL, this cellular debris may linger, triggering an immune reaction against the body’s own tissues. The connection is associative rather than definitively causal at this stage, but it adds an important dimension to MBL deficiency beyond just infection risk. Interestingly, SLE patients as a group actually show elevated MBL blood levels on average, likely as part of the inflammatory response itself.¹³ The paradox, high MBL in active lupus but MBL deficiency as a risk factor for developing lupus, underscores how complex complement biology really is.

MBL Deficiency and Pregnancy Loss

An area of growing interest is the link between low MBL and adverse pregnancy outcomes. The placenta is an immunologically active tissue, and complement regulation there matters for maintaining a healthy pregnancy. Several studies have found that women with recurrent pregnancy loss are significantly more likely to have low MBL levels than women with uneventful pregnancies. In one study, about 45% of women with recurrent pregnancy loss had MBL levels at or below 500 micrograms per liter, compared to about 25% in a reference group.¹⁴

The association appears strongest for unexplained pregnancy losses, the cases where no other clear cause can be identified. In one study of women with recurrent late pregnancy losses in the second trimester, nearly 37% of those with no other identifiable cause carried MBL2 genotypes associated with deficiency, compared to about 13% of controls. The odds of carrying such a genotype were roughly four times higher in the unexplained group.¹⁵ Reduced MBL has also been associated with preterm labor and unexplained intrauterine fetal death in additional research.¹⁶

The proposed mechanism involves excessive or poorly regulated inflammation at the maternal-fetal interface. Without sufficient MBL, complement activation may become dysregulated in ways that damage placental tissue. This is still a research area rather than a clinical routine; MBL testing is not standard in fertility workups. But for women with multiple unexplained losses and no other identified cause, it is a factor some immunologists are beginning to consider.

The Unexpected Upside in Heart Attacks

Here is where MBL deficiency flips the script. During a heart attack, when blood flow is restored to oxygen-starved heart tissue (a process called reperfusion), the complement system can paradoxically worsen the damage. Complement proteins attack the stressed heart cells as though they were foreign invaders, amplifying inflammation and killing tissue that might otherwise have survived. In mouse studies, animals lacking MBL were protected from this reperfusion injury, preserving cardiac function significantly better than mice with normal MBL levels.¹⁷

Blocking MBL pharmacologically produced similar results. In one experiment, a monoclonal antibody that inhibited MBL reduced infarct size by about 39% and neutrophil infiltration by about 47% compared to controls.¹⁸ This has led some researchers to speculate that low MBL might have provided a survival advantage historically in populations prone to cardiovascular events, which could partly explain why MBL deficiency alleles have persisted at such high frequencies. It also raises the possibility that MBL inhibitors, rather than MBL replacement, could someday be used in cardiac care.

How MBL Deficiency Is Diagnosed

If your doctor suspects an MBL deficiency, testing typically involves measuring the protein concentration in your blood and, ideally, assessing whether the lectin complement pathway is functionally active. A simple blood draw can determine MBL levels, which are usually categorized as sufficient, intermediate, or deficient based on defined thresholds. ELISA-based assays have been developed and validated that can evaluate the functional activity of all three complement pathways, including the MBL-driven lectin pathway, helping clinicians identify exactly where a complement deficiency lies.¹⁹

Genetic testing of the MBL2 gene can also be performed to identify which structural mutations and promoter variants a person carries. This provides a lifelong answer, since your MBL genotype does not change, whereas blood levels can fluctuate somewhat because MBL is an acute-phase reactant that rises during inflammation. In practice, most immunologists look at both the protein level and the clinical picture before deciding that MBL deficiency is meaningfully contributing to a patient’s symptoms. A low lab value in someone who is otherwise well is not, by itself, a reason for concern.

Treatment and Management Options

There is no widely available, approved MBL replacement therapy as of now, though the concept has been explored. Early-phase clinical trials of plasma-derived MBL replacement showed that it was feasible and safe, and development of recombinant MBL for therapeutic use has been pursued.²⁰ However, progress has been slow, partly because the majority of MBL-deficient individuals do not become seriously ill and the commercial incentive for a replacement product has been limited.

In practice, management focuses on supporting the rest of the immune system. Vaccination is a cornerstone. MBL-deficient adults with recurrent respiratory tract infections have been shown to produce adequate antibody responses to pneumococcal vaccine, making vaccination a worthwhile strategy even though the underlying lectin-pathway deficit persists.²¹ By strengthening the adaptive immune response through vaccination, clinicians aim to compensate for the gap left by weak innate immunity. Influenza vaccines and other routine immunizations are similarly encouraged.

For patients whose MBL deficiency coincides with other immune deficits, such as low immunoglobulin levels, treatment of the coexisting condition often reduces infection frequency substantially. Immunoglobulin replacement therapy, for instance, addresses the antibody shortfall and can cover for the absent MBL-mediated opsonization to some degree. Prophylactic antibiotics are used selectively in patients with severe recurrent infections, though this is a clinical judgment call rather than a blanket recommendation for anyone with low MBL.

Children passing through the vulnerability window between roughly five and eighteen months may benefit from heightened vigilance by parents and pediatricians: prompt evaluation of fevers, awareness that respiratory infections may recur more often than expected, and in some cases earlier-than-usual administration of certain vaccines. Most children with MBL deficiency outgrow the period of greatest risk once their adaptive immune system matures.

Why MBL Deficiency Is Hard to Pin Down Clinically

One of the frustrating aspects of MBL deficiency for both patients and doctors is its variability. Two people with identical MBL2 genotypes can have vastly different clinical experiences. One may suffer repeated bouts of pneumonia starting in childhood; the other may live to old age without a single unusual infection. This inconsistency reflects the deep redundancy built into human immunity. The complement system has three activation pathways, and even within innate immunity there are multiple overlapping recognition and killing mechanisms. MBL is just one piece of a layered defense, and whether its absence matters depends on how well the rest of the system is functioning.

Compounding the difficulty, MBL levels in the blood are partly influenced by inflammation. Because MBL is an acute-phase protein, its concentration rises during infection or tissue damage. A single blood test during an illness might show a “normal” MBL level that masks an underlying genetically determined deficiency. Conversely, a very low reading during a healthy period might look alarming but carry no clinical significance if the person never gets sick. This is why immunologists tend to combine protein-level measurements with genotyping and a careful review of the patient’s infection history before labeling someone as clinically MBL deficient.

MBL Deficiency and Susceptibility to Intracellular Pathogens

While MBL deficiency clearly leaves gaps in defense against fungi and some extracellular bacteria, there is a longstanding hypothesis that low MBL could actually be protective against certain intracellular pathogens. Organisms like Mycobacterium tuberculosis and Leishmania live inside host cells, and some of them exploit complement-mediated entry to get there. In theory, without MBL tagging these organisms for uptake, fewer pathogens enter the cells where they thrive. The B variant of MBL2 reaches particularly high frequencies in South American indigenous populations, and the C variant is common in sub-Saharan Africa, both regions where intracellular infections have historically been major killers.⁵

This remains debated. The genetic evidence for active selection favoring MBL deficiency alleles is not conclusive; the neutral-evolution explanation, that drift and migration alone explain the pattern, fits the data at least as well.⁶ But the possibility that low MBL is not purely a disadvantage remains an important nuance. It cautions against viewing MBL replacement therapy as a straightforward improvement. Restoring MBL in everyone who lacks it could, at least theoretically, increase vulnerability to the very intracellular infections that some populations may have adapted to evade.

Living With MBL Deficiency Day to Day

If you have been told your MBL levels are low or that you carry MBL2 mutations, the most useful thing to understand is that context determines consequence. For a healthy adult with no history of unusual infections, the finding is usually incidental and does not warrant any specific treatment. Keeping up to date with vaccines, practicing good hygiene, and paying attention to your body’s infection signals are sensible steps, but they are the same advice that applies to everyone.

Where MBL deficiency becomes actionable is in people who have a documented pattern of recurrent or unusually severe infections, especially fungal infections or respiratory infections that keep coming back despite appropriate treatment. In those cases, confirming MBL deficiency can guide decisions about vaccination strategy, prophylactic measures, and whether to investigate other coexisting immune deficits. It can also be a relevant piece of the puzzle in the evaluation of recurrent pregnancy loss when other causes have been ruled out. The immune system’s built-in redundancy means that for most MBL-deficient people, the missing protein remains a laboratory curiosity rather than a clinical crisis, but for the minority where it does matter, identification and targeted management can make a meaningful difference.